Telix Pharmaceuticals Limited (ASX:TLX) entered into an agreement to acquire IsoTherapeutics Group, LLC for $13.6 million on February 26, 2024. As for consideration, purchase price comprises, $8 million upfront, which is payable at closing in the form of $2 million and $6 million in ordinary shares, equating to approximately 0.82 million ordinary shares, $5 million performance-related milestone payments, payable in cash, that are subject to meeting milestone conditions within twelve months of closing, and a two-year revenue share based on actual revenue earned from existing customers of IsoTherapeutics total estimated cash payments $0.6 million. Transaction is subject to Closing of the customary conditions, including regulatory approvals.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
18.15 AUD | +15.31% | +17.32% | +80.06% |
May. 31 | Telix Pharma Reports Positive Data from Clinical Study of Prostate Cancer Drug; Shares Surge 15% | MT |
May. 31 | Commodity, banking stocks help Australian shares snap 3-day slide | RE |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+80.06% | 4.03B | |
+43.34% | 54.64B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- TLX Stock
- News Telix Pharmaceuticals Limited
- Telix Pharmaceuticals Limited entered into an agreement to acquire IsoTherapeutics Group, LLC for $13.6 million.